The natural tumor suppressor protein maspin and potential application in non small cell lung cancer

Current Pharmaceutical Design

Volumn 16, Issue 16, 2010, Pages 1877-1881

  Lonardo, Fulvio ^a   Li, Xiaohua ^a   Kaplun, Alexander ^a   Soubani, Ayman ^a   Sethi, Seema ^a   Gadgeel, Shirish ^a   Sheng, Shijie ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

And differential expression; Drug discovery; Histological subtypes; Histone deacetylase 1; Lung cancer; Molecular marker; Natural HDAC inhibitor; Prognosis; Subcellular localization

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; MASPIN; MOLECULAR MARKER; SERINE PROTEINASE INHIBITOR; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESEARCH; CELLULAR DISTRIBUTION; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; HUMAN; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG DESIGN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEIN TRANSPORT; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953518538     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791208974     Document Type: Article

References (54)

1. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al, The role of histology with common first-line regimens foradvanced non-small cell lung cancer: a brief report of theretrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009; 4: 1568-71.
2. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooledanalysis of the prospective trials of gefitinib monotherapy forEGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58:95-103.
3. Panani AD, Roussos C. Cytogenetic and molecular aspects of lungcancer. Cancer Lett 2006; 239: 1-9.
4. Sy SM, Wong N, Lee TW, Tse G, Mok TS, Fan B, et al, Distinctpatterns of genetic alterations in adenocarcinoma and squamouscell carcinoma of the lung. Eur J Cancer 2004; 40: 1082-94.
5. Blankenburg F, Hatz R, Nagel D, Ankerst D, Reinmiedl J, Gruber C, et al. Preoperative CYFRA 21-1 and CEA as prognostic factorsin patients with stage I non-small cell lung cancer: externalvalidation of a prognostic score. Tumour Biol 2008; 29: 272-7.
6. Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliott WM, et al., Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clusteringanalysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204: 101-9.
7. Ishida T, Kaneko S, Tateishi M, Oka T, Mitsudomi T, Sugimachi K, et al. Large cell carcinoma of the lung. Prognostic implicationsof histopathologic and immunohistochemical subtyping. Am J Clin Pathol 1990; 93: 176-82.
8. Brockmann M, Brockmann I, Herberg U, Muller KM. Adeno-carcinoma of the lung. Immunohistochemical findings (keratin/CEA). J Cancer Res Clin Oncol 1987; 113: 379-82.
9. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, et al. Role for DNA methylation in the control of cell typespecific maspin expression. Nat Genet 2002; 31: 175-9.
10. Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006;12: 7279-83.
11. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, et al. Maspin, a serpin with tumor-suppressing activity in humanmammary epithelial cells. Science 1994; 263: 526-9.
12. Sheng S. The promise and challenge toward the clinical applicationof maspin in cancer. Front Biosci 2004; 9: 2733-45.
13. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, Lonardo F. Nuclear, compared with combined nuclear and cytoplasmicexpression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology 2009; 54: 590-7.
14. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, et al. Maspin nuclear localization is linked to favorable morphologicalfeatures in pulmonary adenocarcinoma. Lung Cancer 2006; 51: 31-9.
15. Pierson CR, McGowen R, Grignon D, Sakr W, Dey J, Sheng S. Maspin is up-regulated in premalignant prostate epithelia. Prostate 2002; 53: 255-62.
16. Marioni G, Staffieri C, Staffieri A, De Filippis C, Blandamura S. MASPIN tumour-suppressing activity in head and neck squamouscell carcinoma: emerging evidence and therapeutic perspectives. Acta Otolaryngol 2009; 129: 476-80.
17. Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, et al. Hightumoral maspin expression is associated with improved survival ofpatients with oral squamous cell carcinoma. Oncogene 2000; 19:2398-403.
18. Takanami I, Abiko T, Koizumi S. Expression of maspin in non-small-cell lung cancer: correlation with clinical features. Clin Lung Cancer 2008; 9: 361-6.
19. Sheng S. A role of novel serpin maspin in tumor progression: thedivergence revealed through efforts to converge. J Cell Physiol 2006; 209: 631-5.
20. Lockett J, Yin S, Li X, Meng Y, Sheng S. Tumor suppressivemaspin and epithelial homeostasis. J Cell Biochem 2006; 97: 651-60.
21. Cher ML, Biliran HR, Jr, Bhagat S, Meng Y, Che M, Lockett J, et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. ProcNatl Acad Sci USA 2003; 100: 7847-52.
22. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspinsensitizes breast carcinoma cells to induced apoptosis. Oncogene 2002; 21: 4089-98.
23. Li X, Yin S, Meng Y, Sakr W, Sheng S. Endogenous inhibition ofhistone deacetylase 1 by tumor-suppressive maspin. Cancer Res 2006; 66: 9323-9.
24. Liu J, Yin S, Reddy N, Spencer C, Sheng S. Bax mediates theapoptosis-sensitizing effect of maspin. Cancer Res 2004; 64: 1703-11.
25. Marioni G, Giacomelli L, D'Alessandro E, Marchese-Ragona R, Staffieri C, Ferraro SM, et al. Nuclear localization of mammaryserine protease inhibitor (MASPIN): is its impact on the prognosisin laryngeal carcinoma due to a proapoptotic effect? Am J Otolaryngol 2008; 29: 156-62.
26. Biliran H, Jr., Sheng S. Pleiotrophic inhibition of pericellularurokinase-type plasminogen activator system by endogenous tumorsuppressive maspin. Cancer Res 2001; 61: 8676-82.
27. McGowen R, Biliran H, Jr., Sager R, Sheng S. The surface ofprostate carcinoma DU145 cells mediates the inhibition ofurokinase-type plasminogen activator by maspin. Cancer Res 2000;60: 4771-8.
28. Yin S, Lockett J, Meng Y, Biliran H, Jr, Blouse GE, Li X, et al. Maspin retards cell detachment via a novel interaction with theurokinase-type plasminogen activator/urokinase-type plasminogenactivator receptor system. Cancer Res 2006; 66: 4173-81.
29. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesisinhibitor. Nat Med 2000; 6: 196-9.
30. Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, et al. Evidence for the epidermal growth factor receptor as atarget for lung cancer prevention. Clin Cancer Res 2002; 8: 54-60.
31. Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal innormal, immortalized, and transformed human bronchial epithelialcells. J Natl Cancer Inst 1999; 91: 373-9.
32. Langenfeld J, Lonardo F, Kiyokawa H, Passalaris T, Ahn MJ, Rusch V, et al. Inhibited transformation of immortalized humanbronchial epithelial cells by retinoic acid is linked to cyclin Edown-regulation. Oncogene 1996; 13: 1983-90.
33. Vannini A, Volpari C, Gallinari P, Jones P, Mattu M, Carfi A, et al. Substrate binding to histone deacetylases as shown by the crystalstructure of the HDAC8-substrate complex. EMBO Rep 2007; 8:879-84.
34. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, et al. Structural snapshots of human HDAC8 provide insights into theclass I histone deacetylases. Structure 2004; 12: 1325-34.
35. Law RH, Irving JA, Buckle AM, Ruzyla K, Buzza M, Bashtannyk-Puhalovich TA, et al. The high resolution crystal structure of thehuman tumor suppressor maspin reveals a novel conformationalswitch in the G-helix. J Biol Chem 2005; 280: 22356-64.
36. Al-Ayyoubi M, Gettins PG, Volz K. Crystal structure of humanmaspin, a serpin with antitumor properties: reactive center loop ofmaspin is exposed but constrained. J Biol Chem 2004; 279: 55540-4.
37. Gao F, Shi HY, Daughty C, Cella N, Zhang M. Maspin plays anessential role in early embryonic development. Development 2004;131: 1479-89.
38. Zhang M, Shi Y, Magit D, Furth PA, Sager R. Reduced mammarytumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene 2000; 19: 6053-8.
39. Li X, Chen D, Yin S, Meng Y, Yang H, Landis-Piwowar KR, et al. Maspin augments proteasome inhibitor-induced apoptosis inprostate cancer cells. J Cell Physiol 2007; 212: 298-306.
40. Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R, Hendrix MJ. maspin suppresses the invasive phenotype of human breastcarcinoma. Cancer Res 1998; 58: 5681-5.
41. Brunmeir R, Lagger S, Seiser C. Histone deacetylase HDAC1/HDAC2-controlled embryonic development and celldifferentiation. Int J Dev Biol 2009; 53: 275-89.
42. Wade PA. Transcriptional control at regulatory checkpoints byhistone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001; 10: 693-8.
43. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, Egger G, et al. Negative and positive regulation of gene expression by mousehistone deacetylase 1. Mol Cell Biol 2006; 26: 7913-28.
44. Vansteenkiste J, Canon JL, Riska H, Pirker R, Peterson P, John W, et al. Randomized phase II evaluation of aprinocarsen incombination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs 2005; 23: 263-9.
45. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, et al. Vorinostat in solid and hematologic malignancies. J HematolOncol 2009; 2: 31.
46. Wiedmann MW, Caca K. Molecularly targeted therapy forgastrointestinal cancer. Curr Cancer Drug Targets 2005; 5: 171-93.
47. Rubin BP, Duensing A. Mechanisms of resistance to smallmolecule kinase inhibition in the treatment of solid tumors. LabInvest 2006; 86: 981-6.
48. Mendelsohn J, Baselga J. Epidermal growth factor receptortargeting in cancer. Semin Oncol 2006; 33: 369-85.
49. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, et al. Histone deacetylases 1 and 2 redundantly regulatecardiac morphogenesis, growth, and contractility. Genes Dev 2007;21: 1790-802.
50. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential incancer therapy. J Cell Biochem 2009; 107: 600-8.
51. Marson CM. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 2009; 9: 661-92.
52. Mahlknecht U, Hoelzer D. Histone acetylation modifiers in thepathogenesis of malignant disease. Mol Med 2000; 6: 623-44.
53. Abbas A, Gupta S. The role of histone deacetylases in prostatecancer. Epigenetics 2008; 3: 300-9.
54. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What arethe cancer relevant targets? Cancer Lett 2009; 277: 8-21.